TransMedics Group (NASDAQ:TMDX) Upgraded to "Buy" at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX - Get Free Report) was upgraded by Needham & Company LLC from a "hold" rating to a "buy" rating in a report issued on Thursday, Marketbeat.com reports. The firm presently has a $148.00 target price on the stock. Needham & Company LLC's price objective would suggest a potential upside of 23.81% from the stock's previous close.

Several other equities analysts have also recently commented on the company. Morgan Stanley boosted their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Stifel Nicolaus assumed coverage on TransMedics Group in a research report on Thursday, September 4th. They set a "hold" rating and a $115.00 price target for the company. Evercore ISI assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They issued an "outperform" rating and a $155.00 target price on the stock. Zacks Research downgraded shares of TransMedics Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 6th. Finally, Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday, October 18th. Eight analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $130.73.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $119.54 on Thursday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The firm has a market cap of $4.08 billion, a price-to-earnings ratio of 61.94 and a beta of 2.08. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $145.50. The business's fifty day moving average is $115.90 and its 200 day moving average is $114.39.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same quarter in the previous year, the firm earned $0.35 EPS. The company's quarterly revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Research analysts predict that TransMedics Group will post 1 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Opal Wealth Advisors LLC bought a new position in TransMedics Group during the second quarter valued at approximately $26,000. Salomon & Ludwin LLC purchased a new stake in shares of TransMedics Group in the 3rd quarter valued at $28,000. Sound Income Strategies LLC bought a new stake in TransMedics Group in the second quarter worth $48,000. Elevation Point Wealth Partners LLC bought a new stake in TransMedics Group in the second quarter worth $48,000. Finally, Smartleaf Asset Management LLC grew its position in TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after acquiring an additional 135 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.